Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
Background
Cited by
Items 601–700 of 1,000
Janyst, K., Janyst, M., Kłopotowska, M., & Lasek, W. (2018) · Oncology Reports · doi:10.3892/or.2018.6248 · Cited by 13
Microenvironmental and Molecular Pathways Driving Dormancy Escape in Bone Metastases
Bakir, M. A., Dabaliz, A., Dawalibi, A., & Mohammad, K. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411893 · Cited by 19
“These medicines promote apoptosis, senescence, and differentiation, while inhibiting angiogenesis and metastatic gene expression; nevertheless, their actions are significantly influenced by environment and tumor type [167,259–264].”
Covid-19 and the Epigenetics of Learning
Johnson, M. W., Maitland, E., & Torday, J. S. (2020) · Postdigital Science and Education · doi:10.1007/s42438-020-00190-9 · Cited by 15
“Epigenetic techniques of DNA methylation (the inhibition of gene transcription) are widespread in agriculture and medicine and their efficacy is beyond doubt (Zhang, Lang and Zhu 2018; Das and Singal 2004; Eckschlager et al. 2017).”
BackgroundHDACi: The Columbus’ Egg in Improving Cancer Treatment and Reducing Neurotoxicity?
Squarzoni, A., Scuteri, A., & Cavaletti, G. (2022) · Cancers · doi:10.3390/cancers14215251 · Cited by 16
“Through their deacetylation and acetylation processes, respectively, these enzymes have a counteractive role on lysine, thus affecting chromatin organization [4] (Figure 1).”
BackgroundInfluentialHDACs as an emerging target in endocrine tumors: a comprehensive review
Klieser, E., Neumayer, B., Fazio, P. D., Mayr, C., Neureiter, D., & Kiesslich, T. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2183840 · Cited by 13
“HDAC11), these classes are considered as classical HDACs based on their dependency on Zn [7,8].”
BackgroundMethodInfluentialRETRACTED ARTICLE: MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer
Liang, Z., Feng, A., & Shim, H. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04024-9 · Cited by 12
RetractedSelective Inhibitors of Histone Deacetylase 10 (HDAC-10)
Pojani, E., & Barlocco, D. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210901144658 · Cited by 12
Jiménez-Alcántar, P., López-Gómez, R., López-Meza, J. E., & Ochoa‐Zarzosa, A. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.801816 · Cited by 12
“Additionally, it is known that iHDACs can activate apoptosis through the production of ROS, which has been demonstrated in several leukemia cell lines (Jurkat, ML-1, U937, HL-60, K-562) (Eckschlager et al., 2017).”
BackgroundPeroxiredoxin2 regulates trophoblast proliferation and migration through SPIB-HDAC2 pathway
Wu, F., Tian, F., Qin, C., Qin, X., Zeng, W., Liu, X., Chen, C., & Lin, Y. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113428 · Cited by 12
Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies
Patel, P., Shrivastava, S. K., Sharma, P. A., Kurmi, B. D., Shirbhate, E., & Rajak, H. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2192804 · Cited by 12
“…HDAC inhibitors belongs to hydroxamic acids category, namely Practinostat (SB939) that inhibits all classical classes of HDACs (I, II and IV) and compound CHR-3996, the selective inhibitor of class I (HDAC1, 2, 3 and 8) is under clinical studies (Eckschlager et al., 2017; Mekala et al., 2022).”
BackgroundChen, J., Jia, X.-H., Xia, X., Wu, X., Xu, Y., Yuan, G., Gu, Z., Luo, K. Q., Yuan, M., Jiang, R., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.144740 · Cited by 12
Croushore, E. E., Koppenhafer, S. L., Goss, K. L., Geary, E. L., & Gordon, D. J. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0268 · Cited by 16
“Fimepinostat is adualinhibitor ofHDACandPI3Ksowethentestedtwoadditional HDACin-hibitorsthatarecurrentlyusedintheclinic,romidepsinandpanobinostat(54).”
Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review
Letafati, A., Soheili, R., Norouzi, M., Soleimani, P., & Mozhgani, S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02166-8 · Cited by 12
Epigenetic Regulation of EMP/EMT-Dependent Fibrosis
Sisto, M., & Lisi, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052775 · Cited by 15
“In addition, it was demonstrated that the different methylation status of specific lysines present in histones can lead to gene induction or suppression.”
BackgroundRobaa, D., Monaldi, D., Wössner, N., Kudo, N., Rumpf, T., Schiedel, M., Yoshida, M., & Jung, M. (2018) · The Chemical Record · doi:10.1002/tcr.201800044 · Cited by 12
Zhu, C., Cai, Y., Zhu, J., Zhang, L., Xing, A., Pan, L., Jia, H., Mo, S., Feng, C. G., Shen, H., et al. (2019) · Tuberculosis · doi:10.1016/j.tube.2019.101861 · Cited by 13
Boulet, M. H. C., Marsh, L. K., Howarth, A., Woolman, A., & Farrer, N. J. (2020) · Dalton Transactions · doi:10.1039/c9dt04862f · Cited by 15
Anticancer Ruthenium Complexes with HDAC Isoform Selectivity
Cross, J. M., Blower, T. R., Kingdon, A. D. H., Pál, R., Picton, D. M., & Walton, J. W. (2020) · Molecules · doi:10.3390/molecules25102383 · Cited by 15
“Five HDAC inhibitors have been approved for clinical use [6].”
BackgroundTilekar, K. N., Hess, J. D., Upadhyay, N., Schweipert, M., Flath, F., Gutiérrez, D. A., Loiodice, F., Lavecchia, A., Meyer‐Almes, F., Aguilera, R. J., et al. (2021) · ChemistrySelect · doi:10.1002/slct.202102061 · Cited by 14
Adewole, K. E., Ishola, A. A., & Olaoye, I. F. (2022) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-021-00191-y · Cited by 12
Genetic inhibitors of APOBEC3B-induced mutagenesis
Mertz, T. M., Rice-Reynolds, E., Nguyen, L. T. H., Wood, A. J., Cordero, C., Bray, N., Harcy, V., Vyas, R. K., Mitchell, D., Lobachev, K. S., et al. (2023) · Genome Research · doi:10.1101/gr.277430.122 · Cited by 14
Shukla, V. K., Siemons, L., Gervasio, F. L., & Hansen, D. F. (2021) · Chemical Science · doi:10.1039/d1sc01929e · Cited by 12
Zhao, H., Zhang, X.-M., Xiao, S., Wu, Z., Shi, Y., & Xie, M.-J. (2023) · PubMed Central · Cited by 15
Acetylation increases expression, interaction with TRAPPC4 and surface localization of PD-L1
Romeo, M. A., Montani, M. S. G., Santarelli, R., Benedetti, R., Arena, A., & Cirone, M. (2023) · Discover Oncology · doi:10.1007/s12672-023-00766-4 · Cited by 11
“HDACi are a novel class of drugs whose anti-cancer activity has been largely demonstrated, also against pancreatic cancer, which is characterized by high aggressiveness and poor response to therapies [8, 9].”
BackgroundUba, A. İ., Hryb, M., Singh, M., Bui-Linh, C., Tran, A., Atienza, J., Misbah, S., Mou, X., & Wu, C. F. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122395 · Cited by 11
The impact of selective HDAC inhibitors on the transcriptome of early mouse embryos
Shao, R., Suzuki, T., Suyama, M., & Tsukada, Y.-I. (2024) · BMC Genomics · doi:10.1186/s12864-024-10029-3 · Cited by 13
“In disease-related applications, HDACi suppress the proliferation of multiple cancer cells or impede the transition of tumor cells toward a malignant phenotype [12].”
Lu, Y., Zhao, Y., Gao, C., Suresh, S., Men, J., Sawyers, A., & Smith, G. L. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113788 · Cited by 13
“50,51 54 Despite extensive studies, the development of selective inhibitors targeting individual HDAC subfamilies remains a challenge due to the conservation of the enzymatic domain.”
Maniaci, A., Giurdanella, G., Chiesa-Estomba, C. M., Mauramati, S., Bertolin, A., Lionello, M., Mayo‐Yáñez, M., Boscolo‐Rizzo, P., Lechien, J. R., & Lentini, M. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14101048 · Cited by 12
“Numerous epigenetic medications, such as HDAC inhibitors and DNA methyltransferase inhibitors, are either being studied in clinical settings or are now being used to treat a variety of malignancies, including laryngeal cancer [64].”
BackgroundHistone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia
Xiao, T., Chen, Z., Xie, Y., Yang, C., Wu, J., & Gao, L. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207241283277 · Cited by 15
Camerino, I., Franco, P., Bajetto, A., Thellung, S., Florio, T., Stoppelli, M. P., & Colucci-D’Amato, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111789 · Cited by 12
“Among them, suberoylanilide hydroxamic acid (SAHA, vorinostat) and trichostatin A (TSA) were first approved by Food and Drug Administration (FDA) for the treatment of several pathologies [17].”
BackgroundHdac1 as an early determinant of intermediate-exhausted CD8 + T cell fate in chronic viral infection
Hu, W., Hu, S. S., Zhu, S., Peng, W., Badovinac, V. P., Zang, C., Zhao, X., & Xue, H. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502256122 · Cited by 14
“There is a growing interest in using Hdac inhibitors for treat-ment of cancers ( 36 , 37 ).”
Insights into novel emerging epigenetic drugs in myeloid malignancies
Chandhok, N. S., & Prébet, T. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719866081 · Cited by 12
Zhang, Y., Fu, T., Ren, Y., Li, F., Zheng, G., Hong, J., Yao, X., Xue, W., & Zhu, F. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00041 · Cited by 12
“Currently, four HDAC inhibitors (HDACi) including Vorinostat, Romidepsin, Panobinostat, and Belinostat have been approved by FDA for anticancer therapeutics, and some other HDAC inhibitors (such as Ricolinostat) are still in the clinical trials to treat hematological and solid malignancies (Yang et al., 2016; Eckschla…”
BackgroundZheng, Z., Xie, J., Xiong, L., Gao, M., Li, Q., Dai, C., Liang, Z., Wang, Y., Xue, J., Wang, Q., et al. (2020) · Medical Oncology · doi:10.1007/s12032-020-01425-2 · Cited by 11
FKBP51 Affects TNF-Related Apoptosis Inducing Ligand Response in Melanoma
Tufano, M., Cesaro, E., Martinelli, R., Pacelli, R., Romano, S., & Romano, M. F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.718947 · Cited by 11
“Among the epigenetic modifiers, HDAC inhibitors are considered promising anti-cancer therapeutics (Eckschlager et al., 2017).”
BackgroundJunker, L. H., Li, Y., Zhu, X., Koti, S., Cerbone, R. E., Hendrick, C. L., Sangerman, J., Perrine, S. P., & Pace, B. S. (2021) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2021.102626 · Cited by 12
Kim, D., Yoon, C., & Lee, G. M. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28013 · Cited by 12
“CI994 is not unique among benzamide‐based iHDACs with respect to enhancing qmAb, and other benzamide‐based iHDACs, namely, MS‐275, mocetinostat, and tucidinostat (Eckschlager et al., 2017; L. Zhang et al., 2018), also increased qmAb by increasing histone acetylation and subsequently mAb mRNA levels.”
BackgroundHDAC2 Is Involved in the Regulation of BRN3A in Melanocytes and Melanoma
Heppt, M. V., Wessely, A., Hornig, E., Kammerbauer, C., Graf, S. A., Besch, R., French, L. E., Matthies, A., Kuphal, S., Kappelmann‐Fenzl, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020849 · Cited by 11
“It is estimated that HDACs control the expression of approximately 2 to 10% of all genes [20].”
BackgroundGnedina, O. O., Morshneva, A. V., Skvortsova, E. V., & Igotti, M. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073517 · Cited by 12
“HDACis exhibit an antiproliferative effect in a wide range of oncogene-transformed and cancer cells, causing cell cycle arrest, premature cell senescence, and programmed cell death [26].”
BackgroundRodríguez, M. D. C. R., García-Rodríguez, I., Nattress, C. B., Qureshi, A., & Halldén, G. (2022) · Viruses · doi:10.3390/v14051006 · Cited by 13
“Inhibition of numerous HDACs with targeted drugs in combination with current therapeutics have shown promise in the clinic [24].”
BackgroundKetogenic Metabolic Therapy for Glioma
Smith, K. A., Hendricks, B. K., DiDomenico, J. D., Conway, B. N., Smith, T. L., Azadi, A., & Fonkem, E. (2022) · Cureus · doi:10.7759/cureus.26457 · Cited by 11
“Temozolomide therapy has been shown to strongly suppress proinflammatory cytokines and escape the immune response as a mechanism of resistance and later tumor recurrence [27].”
BackgroundPanobinostat enhances NK cell cytotoxicity in soft tissue sarcoma
Lu, X., Liu, M., Yang, J., Que, Y., & Zhang, X. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac068 · Cited by 15
Celesia, A., Notaro, A., Franzò, M., Lauricella, M., D’Anneo, A., Carlisi, D., Giuliano, M., & Emanuele, S. (2022) · Biomedicines · doi:10.3390/biomedicines10081994 · Cited by 12
“HDACI have been also shown to specifically induce the expression of genes involved in cell differentiation and apoptosis [26].”
BackgroundValproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis
Sullivan, J., Fahey, P. P., Agho, K. E., Hurley, S. P., Feng, Z., Day, R. O., & LIM, D. J. (2022) · Neuro-Oncology Practice · doi:10.1093/nop/npac078 · Cited by 13
Wang, W., Shen, Y., Zhang, P., Liu, L., Sha, X., Li, H., Wang, S., Zhang, H., Zhou, Y. L., & Shi, J. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1000 · Cited by 11
“Protein acetylation is a favorable target for designing new drugs against many diseases (29,30).”
BackgroundDiagnostic, prognostic, and immunological roles of CD177 in cervical cancer
Liao, W., Li, W., Li, Y., Liu, T., Wang, Y., Feng, D., & Shen, F. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04465-5 · Cited by 11
“CD177 expression may have particular guiding significance for the clinical selection of Belinostat for cervical cancer patients.”
BackgroundInfluentialBanerjee, S., Baidya, S. K., Adhikari, N., & Jha, T. (2022) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2022.2155241 · Cited by 11
“with other anticancer agents may be fruitful in achieving potential anticancer therapeutics [8].”
BackgroundEpigenetic Regulation of Driver Genes in Testicular Tumorigenesis
von Eyben, F. E., Kristiansen, K., Kapp, D. S., Hu, R., Preda, O., & Nogales, F. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044148 · Cited by 14
“…Federal Drug Administration (FDA) has approved seven epidrugs such as 5-aza, 5-aza-cD, belinostat, paninostat, PXD-101, romidepsin, and vorinostat as routine treatment for cutaneous T cell lymphoma, chronic myelomonocytic leukemia (CMML), and multiple myeloma, respectively (Table 2) [198–204].”
BackgroundTo, K. K. W., Cheung, K. M., & Cho, W. C. S. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04641-1 · Cited by 11
“By modifying the chromatin architecture, HDACIs were known to induce pro-apoptotic and cell cycle regulatory genes by modifying the chromatin configuration to elicit their anticancer effect (Eckschlager et al. 2017).”
BackgroundChandrasekaran, B., Tapadar, S., Wu, B., Saran, U., Tyagi, A., Johnston, A., Gaul, D. A., Oyelere, A. K., & Damodaran, C. (2023) · Cancers · doi:10.3390/cancers15061769 · Cited by 11
“To support the notion, several preclinical studies validated that the inhibition of HDACs suppresses the proliferation of PCa by degrading AR expression, resulting in the abrogation of AR signaling [12,14,15].”
BackgroundValinciute, G., Ecker, J., Selt, F., Hielscher, T., Sigaud, R., Ridinger, J., Thatikonda, V., Gatzweiler, C., Robinson, S., Talbot, J., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04319-1 · Cited by 11
“While HDACis showed only moderate clinical success as single therapeutics [13], combination therapy shows preclinical activity [11].”
BackgroundKetogenic Diet Reduces Age-Induced Chronic Neuroinflammation in Mice
Newman, J. C., Nomura, M., Murad, N. F., Madhavan, S. S., Mu, W., Eap, B., Garcia, T. Y., Aguirre, C. G., Verdin, E. M., Ellerby, L., et al. (2024) · doi:10.59368/agingbio.20240038 · Cited by 19
Spirig, S. E., Herrero-Navarro, Á., Utz, L., Arteaga-Moreta, V. J., Raics, Z., Posada-Céspedes, S., Chreng, S., Galuba, O., Galuba, I., Claerr, I., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.02.024 · Cited by 11
Ferroni, C., & Varchi, G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180913095239 · Cited by 11
Jangra, A., Choi, S. A., Koh, E. J., Moon, Y. J., Wang, K., Phi, J. H., Lee, J. Y., & Kim, S. (2019) · Child s Nervous System · doi:10.1007/s00381-019-04099-y · Cited by 11
“This result provides an explanation about why HDAC inhibition does not always increase the expression of the affected genes even if the chromatin structure is loosened [22].”
BackgroundHistone Deacetylase 2 (HDAC2) Inhibitors Containing Boron
Kavianpour, P., Gemmell, M., Kahlert, J. U., & Rendina, L. M. (2020) · ChemBioChem · doi:10.1002/cbic.202000131 · Cited by 11
Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond
Precilla, S. D., Kuduvalli, S. S., & Anitha, T. S. (2020) · Cell Biology International · doi:10.1002/cbin.11484 · Cited by 14
“histone deacetylation, yet it has additionally been appeared to downregulate MGMT in GBM cells (Eckschlager et al., 2017).”
BackgroundJiang, N., Zhang, X., Qin, D., Yang, J., Wu, A., Wang, L., Sun, Y., Li, H., Shen, X., Lin, J., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.608017 · Cited by 11
“Vorinostat was the first histone deacetylase inhibitor (HDI) authorized by the Food and Drug Administration of the United States for cutaneous T-cell lymphoma (CTCL) treatment in 2006, showing great effect on inducing cancer cell death, reducing angiogenesis, and modulating the immune response (Duvic and Dimopoulos, 2…”
BackgroundHuge, N., Reinkens, T., Buurman, R., Sandbothe, M., Bergmann, A. K., Wallaschek, H., Vajen, B., Stalke, A., Decker, M., Eilers, M., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02582-2 · Cited by 11
Epigenetic regulation of cancer stem cells: Shedding light on the refractory/relapsed cancers
Xu, L., Zhang, J., Sun, J., Hou, K., Yang, C., Guo, Y., Liu, X., Kalvakolanu, D. V., Zhang, L., & Guo, B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115110 · Cited by 11
Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal
Boateng, A. T., Abaidoo-Myles, A., Bonney, E. Y., & Kyei, G. B. (2022) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0195 · Cited by 14
Zeng, F., Liu, X., Wang, K., Zhao, Z., & Li, G. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0740 · Cited by 13
“HDAC1 is one of the core members of class I histone deacetylases (HDAC), which serve functional roles including modification of histone and nonhistone proteins, repression or activation of gene expression, regulation of chromatin structure, and cellmetabolism (47, 48).”
Backgrounddiman, S. A., Mohammadzadeh, M., & Pazhang, Y. (2019) · EXCLI journal · doi:10.17179/excli2019-1581 · Cited by 12
“Moreover, HDAC inhibitors showed anticancer effects in some cancer cell lines (Eckschlager et al., 2017).”
BackgroundDayanidhi, D. L., Somarelli, J. A., Mantyh, J. B., Rupprecht, G., Roghani, R. S., Vincoff, S., Shin, I., Zhao, Y., Kim, S. Y., McCall, S. J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.999004 · Cited by 10
“FK228, also known as romidepsin, has already been approved for the treatment of lymphoma (29), suggesting our screening strategy is capable of identifying natural products with efficacy as anticancer agents.”
BackgroundTalom, A., Barhoi, A., Jirpu, T., Dawn, B., & Ghosh, A. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03995-x · Cited by 15
“They are classified into five principal chemical classes: aliphatic fatty acid (valproic acid), hydroxamates (vorinostat, belinostat, pan-obinostat), benzamide derivatives (entinostat, tucidinostat), cyclic peptides (romidepsin), and sirtuin inhibitors (sirtinol, nicotinamide) [37, 38].”
Thiazole derivatives in cancer therapy: mechanistic insights, bioactivity, and future perspective
Saini, H., Mehra, A., & Mittal, A. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2550929 · Cited by 10
Ishikawa, C., & Mori, N. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13508 · Cited by 11
Hałasa, M., Łuszczki, J. J., Dmoszyńska‐Graniczka, M., Baran, M. T., Okoń, E., Stepulak, A., & Wawruszak, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168573 · Cited by 12
Aru, B., Günay, A., Demirel, G. Y., Gürek, A. G., & Atílla, D. (2021) · RSC Advances · doi:10.1039/d1ra05404j · Cited by 10
The role of histone deacetylase 3 in breast cancer
Rahbari, R., Rasmi, Y., Ansari, M. H. K., & Abdi, M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01681-4 · Cited by 12
“Altered gene expression results from post-translational modifications of histone N-terminal tails by several proteins and specific enzymatic complexes [10].”
BackgroundInfluentialVisintin, R., & Ray, S. K. (2022) · Cells · doi:10.3390/cells11244063 · Cited by 14
Synthesis and Antitumor Evaluation of Biotin-SN38-Valproic Acid Conjugates
Dai, Y. M., Zhang, Y., Ye, T., & Chen, Y. (2023) · Molecules · doi:10.3390/molecules28093936 · Cited by 10
“Therefore, histone deacetylase inhibitors (HDACis) have been widely explored for the treatment of cancer [16,17].”
BackgroundCircumvention of Gefitinib Resistance by Repurposing Flunarizine via Histone Deacetylase Inhibition
To, K. K. W., Chow, J. C. H., Cheung, K. M., & Cho, W. C. S. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00202 · Cited by 10
Man, E., & Evran, S. (2023) · Current Genomics · doi:10.2174/0113892029265046231011100327 · Cited by 11
SIN3B Loss Heats up Cold Tumor Microenvironment to Boost Immunotherapy in Pancreatic Cancer
Zhang, Z., Tang, Y., Wang, Y., Xu, J., Yang, X., Liu, M., Mazzone, M., Niu, N., Sun, Y., Tang, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202402244 · Cited by 15
Smith, K. H., Trovillion, E. M., Sholler, C., Gandra, D., McKinney, K. Q., Mulama, D. H., Dykema, K. J., Nagulapally, A. B., Oesterheld, J. E., & Sholler, G. L. S. (2024) · Cancers · doi:10.3390/cancers16213565 · Cited by 10
Attia, S. M., Al‐Hamamah, M. A., Alotaibi, M. R., Harisa, G. I., Attia, M. M., Ahmad, S. F., Ansari, M. A., Nadeem, A., & Bakheet, S. A. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.002 · Cited by 10
Strategies to Enhance Radiosensitivity to Heavy Ion Radiation Therapy
Lee, Y., & Okayasu, R. (2018) · International Journal of Particle Therapy · doi:10.14338/ijpt-18-00014.1 · Cited by 10
“Several HDAC inhibitors have been approved in clinical use for cancer therapy [53], and the use of the HDAC inhibitors would be a promising strategy for heavy ion radiation therapy.”
MethodSugimoto, Y., Katsumi, Y., Iehara, T., Kaneda, D., Tomoyasu, C., Ouchi, K., Yoshida, H., Miyachi, M., Yagyu, S., Kikuchi, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0243 · Cited by 10
Yang, C.-L., Chao, Y., Wang, H., Hou, Y., Chen, C. G., Chang, C., & Shan, Y. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102450 · Cited by 12
Fungal Lysine Deacetylases in Virulence, Resistance, and Production of Small Bioactive Compounds
Bauer, I., & Graessle, S. (2021) · Genes · doi:10.3390/genes12101470 · Cited by 13
“Unfortunately, the repertoire of isoformselective inhibitors is currently still small, and their effects on fungi are largely unexplored yet [155].”
BackgroundUntargeted LC-MS/MS Metabolomics Study on the MCF-7 Cell Line in the Presence of Valproic Acid
Estrada-Pérez, A. R., Rosales‐Hernández, M. C., García-Vázquez, J. B., Bakalara, N., Fromager, B., & Correa‐Basurto, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052645 · Cited by 11
“Therefore, HDAC inhibitors have been studied and developed as promising anticancer agents [12].”
BackgroundManolis, A. S., Manolis, T. A., Mikhailidis, D. P., & Manolis, A. S. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1513489 · Cited by 10
“role in transcription regulation of eukaryotic cells [45].”
BackgroundExploiting ING2 Epigenetic Modulation as a Therapeutic Opportunity for Non-Small Cell Lung Cancer
Blondel, A., Benberghout, A., Pedeux, R., & Ricordel, C. (2019) · Cancers · doi:10.3390/cancers11101601 · Cited by 11
“To date, HDAC inhibitors have only been approved for T cell-lymphoma (vorinostat, romidepsin, and belinostat) and multiple myeloma (panobinostat), but many clinical trials are ongoing in solid tumors [85].”
BackgroundContribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma
Mastoraki, A. T., Schizas, D., Charalampakis, N., Naar, L., Ioannidi, M., Tsilimigras, D. I., Sotiropoulou, M. G., Moris, D., Vassiliu, P., & Felekouras, E. S. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00454-x · Cited by 10
Kase, N., Terashima, M., Ohta, A., Niwa, A., Honda‐Ozaki, F., Kawasaki, Y., Nakahata, T., Kanazawa, N., & Saito, M. K. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0198 · Cited by 10
Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators
Rauscher, S., Greil, R., & Geisberger, R. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009620666210108102723 · Cited by 11
Epigenetic modulators for brain cancer stem cells: Implications for anticancer treatment
Abballe, L., & Miele, E. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i7.670 · Cited by 13
Schweipert, M., Jänsch, N., Upadhyay, N., Tilekar, K. N., Wozny, E., Basheer, S., Wurster, E., Müller, M., Ramaa, C. S., & Meyer‐Almes, F. (2021) · Pharmaceuticals · doi:10.3390/ph14101032 · Cited by 10
“This applies also to HDAC inhibitory drugs like Vorinostat [12], Belinostat [13], and Panobinostat [14], which are approved for the treatment of cutaneous T-cell lymphoma.”
BackgroundCho, H., Yoon, D. H., Kim, K., Bae, K., Kim, W. S., Eom, H., Kim, J. S., Hong, J. Y., Kim, S. J., Lee, H., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0582-0 · Cited by 10
“Fatigue and gastrointestinal toxicities such as nausea, constipation, and diarrhea are common toxicities of HDAC inhibitor treatment, but no patients experienced grade 3/4 fatigue or gastrointestinal toxicities in this study [2].”
BackgroundProteomic insights into lysine acetylation and the implications for medical research
Alonso-Bastida, R., & Encarnación‐Guevara, S. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1557050 · Cited by 12
“These inhibitors were also shown to enhance memory formation and synaptic plasticity in mice [16].”
BackgroundDrug Discovery and Development for Kinetoplastid Diseases
Caffrey, C. R., Steverding, D., Ferreira, R. S., de Oliveira, R. B., O’Donoghue, A. J., Monti, L., Ballatore, C., Bachovchin, K. A., Ferrins, L., Pollastri, M. P., et al. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc235.pub2 · Cited by 17
Design, synthesis and antitumor activity evaluation of novel benzamide HDAC inhibitors
Cai, C., & Luan, Y. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03210-6 · Cited by 9
Histone Deacetylases in Metabolism: the Known and the Unexplored
Ibrahim, S. Y., Carter, J., & Bagchi, R. A. (2024) · Physiology · doi:10.1152/physiol.00044.2024 · Cited by 10
Narukawa, T., Yasuda, S., Horinaka, M., Taniguchi, K., Tsujikawa, T., Morita, M., Ukimura, O., & Sakai, T. (2024) · Cancers · doi:10.3390/cancers16234058 · Cited by 9
“…deacetylase (HDAC) inhibitors have been reported to have anti-tumor effects, and some HDAC inhibitors, such as vorinostat, romidepsin, and panobi-nostat, have been approved by the United States Food and Drug Administration (FDA) for treating peripheral T cell lymphoma and multiple myeloma [11–14].”
Use of DNA methylation patterns for early detection and management of lung cancer: Are we there yet?
Kontić, M., & Marković, F. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.057231 · Cited by 12
“This results in cell cycle arrest, apoptosis, and differentiation [51,52].”
Thiazolidinedione derivatives: emerging role in cancer therapy
Latambale, G., & Juvale, K. (2025) · Molecular Diversity · doi:10.1007/s11030-024-11093-3 · Cited by 14
“They accomplish this by removing acetyl groups from lysine residues on histones, thereby affecting chromatin structure and function [109].”
Tout, I., Bougarn, S., Toufiq, M., Gopinath, N., Hussein, O., Sathappan, A., Chin-Smith, E. C., Rehaman, F., Mathew, R., Mathew, L. S., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06176-0 · Cited by 10
“HDAC dysregulation occurs across various cancer subtypes, and HDACis represent promising anticancer therapies, with few of them (e.g., Vorinostat and Dorminostat) being approved by the Food and Drug Administration (FDA) for the treatment of hematological malignancies [18].”
Unveiling the therapeutic potential of 1,2,4-oxadiazole derivatives: An updated review
Khasawneh, H. E. N., Alrikabi, A. A. A., AL-Erjan, A. M., Kadham, M. J., Al-Aouadi, R. F. A., Lakshmaiya, N., Muhayyo, R., Bräse, S., & Farhan, H. M. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102271 · Cited by 16
The effects of STAT3 acetylation on the transcriptional activity and tumorigenesis
Yan, H., Tang, L., Zhu, Y., & Zhang, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117076 · Cited by 11
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
